Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.
Samantha Brongiel, PharmD, BCOP
Advertisement
Articles by Samantha Brongiel, PharmD, BCOP
The agent is representative of a new class of drug, ImmTAC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Scrutiny of GLP-1 Compounding Is Just Getting Started, Expert Says
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2
4
Menin Inhibitors in AML: Frequently Asked Questions
5